Megan Lynch/LinkedIn
Jun 16, 2026, 16:17
Megan Lynch: Thrilled to Join AstraZeneca
Megan Lynch, Global Product Leader, Cell Therapy Enterprise at AstraZeneca, shared a post on LinkedIn:
“I’m thrilled to share that I’m joining AstraZeneca as a Global Product Leader, Cell Therapy Enterprise.
Cell therapy is transforming how we treat patients across hem/onc, autoimmune, and rare disease.
Getting innovative medicines to patients and providers has always been my north star and I can’t wait to dig in.
Thank you to Margie Li, Margaret DiGuardo, Carsten Linnemann, Craig Maxwell, and Eva Piqué for your partnership throughout this process — I’m looking forward to what we’ll build together.
Here’s to what’s next.”
Stay updated with Hemostasis Today.
-
Jun 19, 2026, 06:11Stephen A. Whelan: How SARS-CoV-2 Infection Reprograms Tryptophan Metabolism
-
Jun 19, 2026, 02:55Strengthening Laboratory Capacity for Earlier Sickle Cell Disease Diagnosis Across Africa – ASH
-
Jun 19, 2026, 00:03Veronica Sanchez: Did You Know That Acute Pulmonary Embolism Can Be Sudden and Serious?
-
Jun 18, 2026, 23:52WFH Regional Conference on Advancing Bleeding Disorders Care
-
Jun 18, 2026, 23:30Vikas Dua: Creating a Future Free From Sickle Cell Disease for Children Worldwide
-
Jun 18, 2026, 22:50Satish C Tajne: MHEI 2026 Marks a Milestone in Advancing Hematology Care
-
Jun 18, 2026, 20:32Julia Owens: A Deep Dive Into Stroke Care and Basking Bio’s Innovative Programs
-
Jun 18, 2026, 19:53Astha Thakkar: What Is the Most Important Test for a Bleeding Disorder?
-
Jun 18, 2026, 19:53Shehab Mohamed: Real-World Evidence on Maternal and Neonatal Outcomes in ITP